Target ( TGT) reported disappointing first-quarter sales, prompting the retailer to issue a lower full-year profit outlook than it previously forecast. First-quarter sales in the U.S. fell 0.6%, worse than the 0.03% decline analysts predicted, according to Thomson Reuters. Target earned $498 million, or 77 cents a share, in the quarter ended May 4, down from its profit of $697 million, or $1.04 a share, in the same quarter last year. Target attributed the weak results to the cooler-than-usual spring weather that weighed on shoppers' seasonal spending. The company now expects adjusted earnings of $4.70 to $4.90 a share for the full year, below the prior forecast of $4.85 to $5.05 that it issued in April. Analysts had expected earnings of $4.48 a share for the full year.
Drugmaker GlaxoSmithKline ( GSK) has received a development deal worth up to $200 million from the U.S. government to create new antibiotics. Per the deal, a first of its kind collaboration between the U.S. government and a drug company, GlaxoSmithKline will focus on developing several drugs that will combat antibiotic resistance and bioterrorism.
The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move. -- Written by Brittany Umar.